Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

Podcast

Dr Nair discusses a study evaluating the role of yoga as a complementary therapy in patients with breast cancer, how these results emphasize the importance of multidisciplinary breast cancer care, and the potential applications of these findings beyond breast cancer.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Nita Nair, MBBS, DNB, MCh, about research she presented at the 2022 San Antonio Breast Cancer Symposium on the role of yoga as a complementary therapy in patients with breast cancer. Dr Nair is a professor of surgical oncology at Tata Memorial Centre in Mumbai, India.

Nair and colleagues conducted a randomized trial to investigate how yoga affected disease-free survival (DFS), overall survival (OS) and quality of life (QOL) in 850 patients with nonmetastatic breast cancer. Although the 15% relative improvement in DFS and 14% improvement in OS in the patients who practiced yoga did not reach statistical significance for this trial, yoga plus conventional exercise was found to be a low-cost, low-risk complementary therapy that improved fatigue, pain, and QOL among patients vs conventional exercise alone.

In our exclusive interview, Dr Nair discussed key data from this trial, how these results emphasize the importance of multidisciplinary breast cancer care, and the potential applications of these findings beyond breast cancer.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Carlos Arteaga, MD
Video 2 - "NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer"
Reshma L. Mahtani, DO
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "